New User:

-or-
Username:
Password:
Forgot your password?
News Breaks
November 9, 2009
07:15 EDTCGEN
theflyonthewall.com: Compugen discovers genetic biomarker for Predisposition to Type 2 diabetes
Compugen announced the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to type 2 diabetes, the most common form of diabetes. This new biomarker was discovered using Compugen’s GeneVa® platform, which consists of an in silico database of approximately 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides. :theflyonthewall.com



News For CGEN From The Last 14 Days
Check below for free stories on CGEN the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing.
February 7, 2012
07:10 EDTCGEN
theflyonthewall.com: Compugen reports Q4 EPS (13c) vs. consensus (10c) (One est)

Subscribe for More Information
:theflyonthewall.com
07:08 EDTCGEN
theflyonthewall.com: Compugen says no revenues recorded for Q4

Subscribe for More Information
:theflyonthewall.com

February 2, 2012
06:14 EDTCGEN
theflyonthewall.com: Compugen announces CGEN-15001T results demonstrating potential

Subscribe for More Information
:theflyonthewall.com

January 30, 2012
07:00 EDTCGEN
theflyonthewall.com: Compugen presents three product candidates for treatment of autoimmune diseases
Speaking today at the 4th Immunotherapeutics & Immunomonitoring Conference in San Diego, Dr. Galit Rotman, Chief Scientist of Therapeutics at Compugen, presented data demonstrating the therapeutic efficacy of CGEN-15001, CGEN-15021 and CGEN-15091 in animal models of multiple sclerosis and the therapeutic efficacy of CGEN-15001 and CGEN-15021 in animal models of rheumatoid arthritis. CGEN-15001, CGEN-15021 and CGEN-15091 are predicted B7/CD28-like proteins discovered using Compugen’s Protein Family Members Discovery Platform. :theflyonthewall.com